Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more
Genomictree Inc. (228760) - Total Assets
Latest total assets as of September 2025: ₩122.89 Billion KRW
Based on the latest financial reports, Genomictree Inc. (228760) holds total assets worth ₩122.89 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genomictree Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Genomictree Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genomictree Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Genomictree Inc.'s total assets of ₩122.89 Billion consist of 74.7% current assets and 25.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩26.35 Billion | 20.2% |
| Accounts Receivable | ₩332.50 Million | 0.3% |
| Inventory | ₩334.58 Million | 0.3% |
| Property, Plant & Equipment | ₩18.39 Billion | 14.1% |
| Intangible Assets | ₩1.25 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Genomictree Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genomictree Inc.'s current assets represent 74.7% of total assets in 2024, a decrease from 89.3% in 2020.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, down from 48.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is cash and equivalents at 20.2% of total assets.
Genomictree Inc. Competitors by Total Assets
Key competitors of Genomictree Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genomictree Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genomictree Inc. generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genomictree Inc. is currently not profitable relative to its asset base.
Genomictree Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.19 | 19.27 | 28.01 |
| Quick Ratio | 17.12 | 19.19 | 27.68 |
| Cash Ratio | 0.00 | 4.27 | 0.00 |
| Working Capital | ₩81.91 Billion | ₩ 92.85 Billion | ₩ 106.93 Billion |
Genomictree Inc. - Advanced Valuation Insights
This section examines the relationship between Genomictree Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.12 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | ₩130.68 Billion |
| Market Capitalization | $278.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genomictree Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Genomictree Inc.'s assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Genomictree Inc. (2020–2024)
The table below shows the annual total assets of Genomictree Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩130.68 Billion | -1.63% |
| 2023-12-31 | ₩132.84 Billion | -18.46% |
| 2022-12-31 | ₩162.91 Billion | -8.04% |
| 2021-12-31 | ₩177.15 Billion | +50.26% |
| 2020-12-31 | ₩117.90 Billion | -- |